Onglyza (saxagliptin) - Important Safety Information from Bristol-Myers Squibb as approved by the Irish Medicines Board
12 March 2012
Important Safety Information communication from Bristol-Myers Squibb on the association of Onglyza (saxagliptin) with serious hypersensitivity reactions and acute pancreatitis.
Important Safety Information - Onglyza